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Abstract
Aims/hypothesis Impaired regulation of lipolysis and accu-
mulation of lipid intermediates may contribute to obesity-
related insulin resistance and type 2 diabetes mellitus. We
investigated insulin-mediated suppression of lipolysis in
abdominal subcutaneous adipose tissue (AT) and skeletal
muscle (SM) of obese men with normal glucose tolerance
(NGT) and obese type 2 diabetic men.
Methods ElevenNGTmen and nine long-term diagnosed type
2 diabetic men (7±1 years), matched for age (58±2 vs 62±
2 years), BMI (31.4±0.6 vs 30.5±0.6 kg/m2) and V
⋅
O2max
(28.9±1.5 vs 29.5±2.4 ml kg−1 min−1) participated in this
study. Interstitial glycerol concentrations in AT and SM were
assessed using microdialysis during a 1 h basal period and a
6 h stepwise hyperinsulinaemic–euglycaemic clamp (8, 20 and
40 mU m−2 min−1). AT and SM biopsies were collected to
investigate underlying mechanisms.
Results Hyperinsulinaemia suppressed interstitial SM glycer-
ol concentrations less in men with type 2 diabetes (−7±6%,
−13±9% and −27±9%) compared with men with NGT
(−21±7%, −38±8% and −53±8%) (p=0.014). This was ac-
companied by increased circulating fatty acid and glycerol
concentrations, a lower glucose infusion rate (21.8±3.1 vs
30.5±2.0 μmol kg body weight−1 min−1; p<0.05), higher
hormone-sensitive lipase (HSL) serine 660 phosphorylation,
increased saturated diacylglycerol (DAG) lipid species in the
muscle membrane and increased protein kinase C (PKC)
activation in type 2 diabetic men vs men with NGT. No
significant differences in insulin-mediated reduction in AT
interstitial glycerol were observed between groups.
Conclusions/interpretation Our results suggest that a blunted
insulin-mediated suppression of SM lipolysis may promote
the accumulation of membrane saturated DAG, aggravating
insulin resistance, at least partly mediated by PKC. This may
represent an important mechanism involved in the progression
of insulin resistance towards type 2 diabetes.
Trial registration: ClinicalTrials.gov NCT01680133
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Introduction
Skeletal muscle (SM) lipid accumulation, and more specifi-
cally the accumulation of lipid metabolites, is strongly asso-
ciated with the development of insulin resistance in the obese
or obese type 2 diabetic state [1]. There are several bioactive
lipid metabolites that may influence muscle insulin sensitiv-
ity, including long-chain acyl-CoA [2], ceramides [3, 4] and
diacylglycerol (DAG) [5]. Although DAG is only a small
fraction of the intramuscular lipid pool, it has potent biolog-
ical effects and is formed during intracellular lipolysis. DAG
is an important second messenger involved in intracellular
signalling and may have detrimental effects on insulin action
through its ability to activate conventional (α, β1, β2, and γ)
and novel (δ, ε, θ, η) protein kinase C (PKC) isoforms in
muscle [6, 7]. On activation, PKCs are redistributed within
the cell, such that the membrane-associated kinase is consid-
ered to be the active form. Importantly, it seems that cellular
localisation and composition of DAG rather than the abso-
lute amount of DAG may be of major importance in insulin
resistance [8].
Lipid overflow from adipose tissue (AT) is considered to
play a significant role in the development of fat accumulation
and insulin resistance [9]. Indeed, the obese insulin-resistant
or obese type 2 diabetic state is characterised by increased
circulating concentrations of NEFA and/or triacylglycerol
(TAG). This increased lipid supply to SM may promote
ectopic fat accumulation [10]. Insulin sensitivity of AT lipol-
ysis is normal [11, 12] or slightly impaired in obese individ-
uals [13, 14]. We have previously shown that in long-term
diagnosed obese type 2 diabetic men with no compensatory
hyperinsulinaemia, the rate of appearance of plasma NEFA is
elevated compared with obese men with normal glucose
tolerance (NGT) [15]. These data indicate resistance to
the antilipolytic effects of insulin, which may significantly
contribute to increased circulating NEFA concentrations in
this population.
Nevertheless, NEFA generated by intramuscular TAG
hydrolysis may also be of importance [16]. We have
recently demonstrated intrinsic disturbances in SM lipolysis,
including an imbalance of adipose TAG lipase (ATGL) rela-
tive to hormone-sensitive lipase (HSL) activity in the obese
insulin-resistant state [17, 18], contributing to muscle lipid
accumulation and the pathogenesis of insulin resistance and
type 2 diabetes [19]. The hormonal regulation of SM lipolysis
is still not completely elucidated [20, 21]. For instance, find-
ings in initial studies that measured interstitial glycerol levels
in vivo suggested a lower [21] or higher [20] antilipolytic
effect of insulin in SM compared with AT. However, investi-
gations in which the fractional release of glycerol was assessed
in situ showed no inhibitory effect of insulin on SM lipolytic
activity [21–23].
In the present study, we investigated insulin-mediated
suppression of abdominal subcutaneous ATand SM lipolysis
during a three-step hyperinsulinaemic–euglycaemic clamp
in patients with long-standing type 2 diabetes compared with
men with NGT. Careful matching of the type 2 diabetic
patients with NGT controls was performed with respect to
age, body composition and physical fitness to determine the
independent effect of type 2 diabetes (e.g. hyperglycaemia)
on insulin-mediated inhibition of tissue lipolysis. ATand SM
biopsy analyses were performed to obtain detailed informa-
tion about gene expression and lipid composition in the
cytosolic and muscle membrane fractions of men with type
2 diabetes and NGT.
Methods
Participants Eleven individuals with NGTand nine with type
2 diabetes matched for age (58±2 vs 62±2 years), BMI
(31.4±0.6 vs 30.5±0.6 kg/m2) and V
⋅
O2max (28.9±1.5 vs
29.5±2.4 ml kg−1 min−1) participated in the study. Type 2
diabetic participants had been diagnosed for at least 5 years
and were not using insulin treatment. Men with NGT had a
fasting plasma glucose (FPG) <6.1 mmol/l (or <5.6 mmol/l
where there was a family history of type 2 diabetes) and a 2 h
plasma glucose <7.8 mmol/l. All participants gave written
informed consent. The Medical–Ethical Committee of Maas-
tricht University approved the study protocol.
Study design All participants were asked to refrain from
alcohol and strenuous exercise for a period of 48 h before
the study days. Blood-glucose and lipid-lowering medica-
tion (metformin n=4, simvastatin n=3) were withdrawn
3 days prior to the study days and participants were asked
to maintain their habitual dietary intake throughout the study.
Individuals came to the laboratory by car or public transport
in the morning after an overnight fast and were in the
supine position for the study. Insulin-mediated suppression
of lipolysis in the abdominal subcutaneous AT and the
gastrocnemius muscle was investigated using microdialysis,
as described below. One week after the clamp, abdominal
subcutaneous AT and SM biopsies were taken, as described
in more detail below.
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Microdialysis On arrival, two microdialysis catheters (CMA
60; CMAMicrodialysis, Stockholm, Sweden) were placed in
abdominal subcutaneous AT 6–8 cm to either side of the
umbilicus, and two microdialysis probes were placed in the
medial part of the gastrocnemius muscle of both legs after
local anaesthesia (Xylocaine 2% without adrenaline [epi-
nephrine]; AstraZeneca, Zoetermeer, the Netherlands) and
under sterile conditions. Thereafter, 90 min were allowed for
recovery of the tissue from the insertion trauma. After inser-
tion, the two probes were perfused with Ringer solution
(Baxter, Utrecht, the Netherlands) at a flow rate of 0.3 μl/min
(one in AT and one in SM). Microdialysate was collected
from these sites in fractions every 30 min for the measure-
ment of interstitial glycerol, glucose, lactate and pyruvate
concentrations (CMA 600Microdialysis Analyzer, Pronexus
Analytical, Stockholm, Sweden). The two contralateral
probes were perfused with Ringer solution supplemented
with 50 mmol/l ethanol at a flow rate of 5.0 μl/min.
Microdialysate was collected from these sites in fractions
every 15 min to assess the ethanol outflow/inflow ratio as an
indicator of local nutritive blood flow [24]. Ethanol concen-
trations were measured spectrophotometrically at 340 nm
using a standard ethanol assay kit (176290; Boehringer,
Mannheim, Germany).
Three-step hyperinsulinaemic–euglycaemic clamp After in-
sertion of the microdialysis probes, two cannulas were
inserted. Arterialised blood was obtained through a 20-gauge
cannula inserted retrogradely into a superficial dorsal hand
vein. The hand was warmed in a hot box (air circulating at
60°C) to achieve adequate arterialisation [25]. In the contra-
lateral arm, a second cannula was introduced anterogradely in
an antecubital vein of the forearm for the infusion of 20%
(wt/vol.) glucose (IVAC560 pump, IVAC, San Diego, CA,
USA) and insulin (Actrapid, Novo Nordisk Farma, Alphen
aan den Rijn, the Netherlands) using a Harvard pump (Plato,
Diemen, the Netherlands). A small amount of blood was
drawn from the dorsal hand vein every 5 min throughout the
clamp to determine glucose concentrations (EML 105, Radi-
ometer, Copenhagen, Denmark). After the collection of three
baseline samples (at −30 min, −15 min and 0 min), a three-
step primed hyperinsulinaemic–euglycaemic clamp was
started with infusion of 8 (0–120 min), 20 (120–240 min)
and 40 mU m−2 min−1 (240–360 min) insulin. The amount of
glucose infused was adjusted to maintain euglycaemia at
baseline glucose concentrations (5.5±0.1 vs 8.6±0.4 mmol/l
in men with NGT and type 2 diabetes, respectively).
Plasma glucose (ABX Pentra Glucose HK CP, Radiometer,
Copenhagen, Denmark), NEFA (NEFAC kit, Wako Chemicals,
Neuss, Germany) and glycerol (EnzyPlus Glycerol kit,
DiffChamp, Västra Frölunda, Sweden) concentrations
were determined with commercially available kits using
standard enzymatic methods. Plasma insulin concentrations
were measured by a specific double-antibody radioimmu-
noassay for human insulin (Linco Research, St Charles,
Missouri, USA).
Abdominal subcutaneous ATand SM biopsies After an over-
night fast an abdominal subcutaneous AT biopsy was col-
lected 6–8 cm lateral from the umbilicus and a vastus
lateralis muscle biopsy was obtained under local anaesthesia
(Xylocaine) using the Bergström needle biopsy technique
[26]. Tissues were snap-frozen in liquid nitrogen and imme-
diately stored at −80°C until further analysis.
Gene-expression analysis Total RNA was extracted from
frozen AT and SM specimens, as described before [17, 18].
The expression of genes involved in the lipolytic pathway
(ATGL [also known as PNPLA2]; HSL [also known as
LIPE]; ABHD5, encoding abhydrolase domain containing 5
(ABHD5); G0S2, G0/G1 switch regulatory protein 2
(G0S2); PLIN1 and PLIN2, encoding perilipin 1 (PLIN1)
and 2; and AQP7, aquaporin 7), glucose transport (GLUT4
[also known as SLC2A4]), insulin signalling (IRS1 and IRS2;
PDE3B, phosphodiesterase 3B), fatty acid transport (CD36,
fatty acid translocase), mitochondrial biogenesis (PGC1α
[also known as PPARGC1A], peroxisome proliferator-activated
receptor γ, coactivator 1 α), lactate signalling (GPR81 [also
known as HCAR1], G protein-coupled receptor 81), and glyc-
erol re-esterification (GK, glycerol kinase) were investigated
in both AT and SM. Gene-expression levels were normalised
using the housekeeping genes 60S ribosomal protein L13a
(RPL13A) and β2-microglobulin (B2M), as GeNorm analysis
demonstrated that these housekeeping genes had the highest
stability.
Antibodies and western blot analysis A rabbit polyclonal
antibody raised against the phosphopeptide based on the
amino-acid sequence of murine ATGL (400–414) pS406
LRRAQpSLPSVPLSC (corresponding to human ATGL
pS404) was purified as described previously [27, 28].
Furthermore, commercially available primary and secondary
antibodies were used as previously described [17, 18].
Muscle tissue was homogenised and resolved by SDS-
PAGE as described before [17, 18, 28].
Membrane fractionation Membrane and cytosolic fractions
were isolated using an ultracentrifugation protocol. Briefly,
muscle biopsies were extracted 1:10 (wt/vol.) in ice-cold basic
buffer (100 mmol/l EDTA, 100 mmol/l EGTA, 1.5 mol/l Tris
and β-glycerolphosphate), protease (Roche Applied Science,
Indianapolis, IN, USA) and phosphatase inhibitors (Sigma,
St Louis, MO, USA) at 4°C. Homogenates were centrifuged
at 160,000 g for 20 min, and the supernatant fraction,
representing the cytosolic fraction, was removed and stored
at −80°C. The pellet was resuspended in triton-supplemented
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buffer and sonicated. After 1 h at 4°C with constant gentle
inversion, the extract was centrifuged at 160,000 g for
20 min, and the supernatant fraction representing the
membrane fraction was saved.
SM lipid composition of cytosolic and membrane fraction
Total lipids were extracted from muscle cytosolic and mem-
brane fractions using chloroform-methanol 2:1 (vol.:vol.).
The extracted lipids were separated into TAG, DAG, fatty
acids and phospholipid by thin-layer chromatography as
described before [18].
Statistics Data are presented as means ± SEM. The overall
effect of hyperinsulinaemia on interstitial and circulating
metabolite levels over time, between groups and time×group
interaction was analysed using repeated-measures ANOVA.
Post hoc testing was performed using Students’ unpaired
t test with Bonferroni adjustment for multiple testing when
ANOVA showed a significant time-over-group effect. Rela-
tionships between lipid species, insulin sensitivity and
insulin-mediated suppression of lipolysis were calculated
using Pearson’s correlation coefficient. Calculations were
performed using SPSS 18.0 for Mac (Chicago, IL, USA).
A value of p<0.05 was considered to be statistically signif-
icant. Calculation of sample size was performed using
GPower (version 3.1 for Mac, Heinrich-Heine University,
Düsseldorf, Germany), indicating that nine individuals per
group would be sufficient to detect a mean difference in
dialysate glycerol concentration of 50 μmol/l, with a power
of 0.8, α 0.05 and SD 25 μmol/l, including an anticipated
drop out of 10% [21].
Results
Participants Participants’ characteristics are shown in
Table 1. Men with NGT and type 2 diabetes had comparable
age, BMI, body fat percentage, WHR and V
⋅
O2max. Type 2
diabetic men had been diagnosed for at least 5 years (average
7±1 years) and had well-controlled glucose concentrations.
As expected, fasting glucose and HbA1c were significantly
higher in the type 2 diabetic group, whereas fasting insulin
concentrations were comparable between groups. Insulin
sensitivity (HOMA-insulin resistance [IR]), was significant-
ly reduced in the type 2 diabetic group compared with the
NGT group.
Circulating metabolite concentrations Plasma insulin con-
centrations were stable during the steady-state of the clamp
and not significantly different between the groups (Fig. 1a).
Blood-glucose concentrations were maintained at fasting
concentrations throughout the entire clamp in both groups
(Fig. 1b). Circulating NEFA and glycerol concentrations were
significantly elevated in type 2 diabetic men during the entire
6 h clamp period (ANOVA group p<0.01; Fig. 1c, d).
Interstitial glycerol Interstitial glycerol concentrations in
abdominal subcutaneous AT were comparable between
groups at baseline (Fig. 2a) and decreased to the same extent
during the clamp in both groups (Fig. 2a, b). At the end of
step 3 (40 mU m−2 min−1), values had decreased by 44±5%
and 47±9% in the AT of men with type 2 diabetes and NGT,
respectively (Fig. 2b).
Baseline SM interstitial glycerol concentrations were sig-
nificantly higher in men with type 2 diabetes compared with
NGT (152±11 vs 119±16 μmol/l; p<0.05, Fig. 2c) and
during the 6 h clamp (ANOVA time×group p=0.043; Fig. 2c;
electronic supplementary material [ESM] Table 1). Muscle
interstitial glycerol concentrations decreased by 7±6%,
13±9% and 27±9% during the subsequent hyperinsulinaemic
steps in type 2 diabetic men, while this decrease was more
pronounced in men with NGT (21±7%, 38±8% and 53±8%;
ANOVA time×group p=0.014, Fig. 2d; ESM Table 1). In line
with this, the absolute decrease from baseline in interstitial
glycerol concentration during hyperinsulinaemia was blunted
in the SM of type 2 diabetic men compared with men with
NGT (ANOVA time×group p=0.041). Tissue nutritive blood
flow, determined using the ethanol outflow/inflow ratio, was
unchanged during hyperinsulinaemia in both groups, indicat-
ing changes in interstitial glycerol concentrations are not due
to alterations in tissue blood flow (ESM Fig. 1).
Glucose infusion rate and interstitial glucose, lactate and
pyruvate The blunted insulin-mediated suppression of SM
glycerol concentration was accompanied by reduced peripheral
Table 1 Participants’ characteristics
Characteristic NGT (n=11) Type 2 diabetes
(n=9)
Age (years) 58±8 62±6
BMI (kg/m2) 31.4±1.8 30.5±2.1
Body fat (%) 30.1±6.2 31.3±4.6
WHR 1.04±0.05 1.05±0.05
V
⋅
O2max (ml min
−1
kg
−1
) 28.9±4.8 29.5±6.7
Glucose (mmol/l) 5.5±0.2 8.6±1.5*
Insulin (pmol/l) 89±33 108±44
HOMA-IR 3.3±1.2 6.0±2.8*
HbA1c (%) 5.6±0.3 6.9±0.6
HbA1c (mmol/mol) 38.20±1.07 52.40±2.19
*
AST (μkat/l) 0.37±0.15 0.42±0.17
ALT (μkat/l) 0.63±0.40 0.67±0.33
Values are means ± SD
* p<0.05 men with NGT vs type 2 diabetes, unpaired samples t test
ALT, alanine aminotransferase; AST, aspartate aminotransferase
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glucose disposal, as indicated by the lower glucose infusion
rate (GIR) at 20mUm−2min−1 (11.6±0.7 vs 15.1±1.1μmol kg
body weight−1 min−1, p<0.05) and 40 mU m−2 min−1
(21.8±3.1 vs 30.5±2.0 μmol kg body weight−1 min−1,
p<0.05) of the clamp in type 2 diabetic men compared with
men with NGT (ESM Fig. 2).
Concentrations of SM lactate, a marker of anaerobic me-
tabolism, were significantly elevated at 40 mU m−2 min−1
during the clamp (ANOVA group p<0.01; Fig. 3e) in type 2
diabetic men. Interstitial AT and SM glucose concentrations
were significantly higher at baseline and during the entire clamp
in type 2 diabetic men (ANOVA group p<0.01; Fig. 3a, d),
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and the three-step 6 h
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clamp (8, 20, 40 mU m−2 min−1)
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(black squares) compared with
nine type 2 diabetic men (white
squares). The response was
compared using ANOVA.
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and NEFA are significantly
different between groups, with
p<0.001, p<0.01 and p<0.01,
respectively. Values are
means ± SEM. B, baseline
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d) showed significant time–
group interaction (p=0.043 and
p=0.014, respectively). Values
are means ± SEM. B, baseline
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while AT and SM pyruvate concentrations were comparable
between groups (Fig. 3c, f).
Gene-expression and protein data As shown in ESMFig. 3a,
ATGLmRNA expression was reduced in the SM of men with
type 2 diabetes compared with NGT (0.70±0.08 vs
1.00±0.10; p=0.041). The expression of HSL mRNA
(0.68±0.14 vs 1.00±0.16; p=0.157) and ABHD5 mRNA
(0.85±0.06 vs 1.00±0.07; p=0.119) was lower in the SM
of type 2 diabetic men, though the difference was not statis-
tically significant. Besides disturbances in ATGL expression,
reduced GLUT4 mRNA (0.77 ±0.06 vs 1.00± 0.06;
p=0.014) and a tendency for lower PDE3B mRNA
(0.59±0.09 vs 1.00±0.26; p=0.072) expression was ob-
served in the SM of type 2 diabetic men. Finally, PGC1α
mRNA expression was lower in the SM of type 2 diabetic
men (0.72±0.09 vs 1.00±0.06; p=0.032). No differences in
AT gene expression were observed between groups (ESM
Fig. 3b).
Muscle ATGL protein content was comparable between
groups (1.00±0.12 vs 0.93±0.18; p=0.737) and muscle HSL
protein content was significantly lower in type 2 diabetic
men (1.00±0.31 vs 0.26±0.14; p=0.037). The ratio of phos-
phorylated ATGL at serine 404 to total ATGL tended to be
lower in the SM of men with type 2 diabetes compared with
NGT (0.78±0.12 vs 1.02±0.09; p=0.117; Fig. 4a), while the
ratio of phosphorylated HSL at serine 660 to total HSL was
increased in the SM of type 2 diabetic men (2.63±0.36 vs
1.00±0.19; p=0.011; Fig. 4b). No differences were observed
in ABHD5 and G0S2 protein content between groups
(Fig. 4c, d). Muscle biopsies were lyophilised and dissect-
ed free of extracellular lipid, blood and connective tissue.
Additionally, PLIN1 was not detectable in any of the
muscle samples, excluding significant contamination by
infiltrated adipocytes.
SM lipid composition of cytosolic and membrane fraction
Enrichment of membrane (i.e. caveolin 2 [CAV] and immu-
noglobulin heavy chain-binding protein [BIP]) and cytosolic
(i.e. glyceraldehyde-3-phosphate dehydrogenase [GAPDH],
ATGL and HSL) markers in their respective subcellular
compartments (ESM Fig. 4) show that the cellular fraction-
ation methods were successful and suggest minor contami-
nation between fractions. The cellular distribution of SM
lipid species is shown in Table 2. Total SM DAG content
was significantly higher in men with type 2 diabetes com-
pared with NGT (p=0.022; Table 2). Most DAG was found
in the membrane fraction. Interestingly, DAG content was
significantly elevated in the SM membrane fraction of type 2
diabetic men compared with men with NGT (p=0.029,
Table 2). Moreover, the saturated DAG species 16:0, 17:0,
18:0, 22:0 and trans18:1 were more abundant in the SM
membrane fraction of men with type 2 diabetes compared
with NGT (ESM Table 2). Interestingly, saturated DAG
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Fig. 3 Interstitial glucose (a, d),
lactate (b, e) and pyruvate
concentrations (c, f) in
subcutaneous AT (a–c) and SM
(d–f) during baseline and the
three-step 6 h
hyperinsulinaemic–euglycaemic
clamp (8, 20, 40 mU m−2 min−1)
in 11 obese men with NGT
(black squares) compared with
nine type 2 diabetic men (white
squares). The response was
compared using ANOVA. AT
and SM glucose (a and d) curves
and SM lactate (e) curves were
significantly different between
groups (p<0.01). Values are
means ± SEM. B, baseline
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content in the SM membrane showed a strong inverse asso-
ciation with insulin sensitivity (GIR: r=−0.568, p<0.01;
Fig. 5a) and the decrease in interstitial muscle glycerol
(r=−0.546, p<0.01; Fig. 5b). Moreover, the increase in
membrane saturated DAG was positively associated with
PKC activation (r=0.376, p<0.01; Fig. 5c) (ratio of PKCδ
membrane to cytosolic in men with type 2 diabetes vs NGT:
6.07±1.19 vs 2.43±0.69; p=0.028; ESM Fig. 5). Cytosolic
DAG concentration showed no relationship with insulin
sensitivity or the decrease in interstitial muscle glycerol.
No differences were observed in total or subcellular TAG,
phospholipid or fatty acid fractions between groups.
0.00
0.20
0.40
0.60
0.80
1.00
1.20
NGT T2DA
TG
L 
S4
04
/to
ta
l A
TG
L
(no
rm
ali
se
d e
xp
res
sio
n)
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
NGT T2D
H
SL
 
S6
60
/to
ta
l H
SL
(no
rm
ali
se
d e
xp
res
sio
n)
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
NGT T2D
AB
H
D
5/
ac
tin
(no
rm
ali
se
d e
xp
res
sio
n)
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
1.4 
NGT T2D
G
0S
2/
ac
tin
(no
rm
ali
se
d e
xp
res
sio
n)
a b
c d
HSL S660
Total HSL
ATGL S404
Total ATGL
ABHD5
α-actin
G0S2 
α-actin
NGT NGT T2D T2D NGT NGT T2D T2D
NGT NGT T2D T2D NGT NGT T2D T2D
†
‡
Fig. 4 SM ATGL serine 404
phosphorylation (a), HSL serine
660 phosphorylation (b),
ABHD5 (c) and G0S2 (d)
protein content in men with NGT
vs type 2 diabetic men. Protein
levels are normalised to men
with NGT and differences in
loading are corrected by α-actin.
PLIN1 protein was not
detectable in any of the muscle
samples excluding significant
contamination by infiltrated
adipocytes. Values are
means ± SEM and significance
was tested using the unpaired
t test. †p=0.117 and ‡p=0.011.
T2D, type 2 diabetes
Table 2 Muscle lipid composition in cytosolic and membrane fractions
Lipid TAG (μmol/mg protein) DAG (μmol/mg protein) PL (μmol/mg protein) FA (μmol/mg protein)
NGT Type 2 diabetes NGT Type 2 diabetes NGT Type 2 diabetes NGT Type 2 diabetes
SFA
Cyto 4.91±0.84 4.67±2.91 14.17±16.26 19.35±11.05 4.68±5.91 4.96±3.35 0.56±0.38 0.95±0.81
Mem 272±157 261±169 55±31 102±51* 250±63 231±45 19.86±9.37 18.37±5.26
MUFA
Cyto 3.39±1.78 4.54±2.87 1.45±0.96 2.29±1.92 0.99±1.18 1.12±0.61 0.19±0.16 0.31±0.16
Mem 340±270 284±181 48±20 52±20 60±16 74±31 6.88±4.65 5.83±2.78
PUFA
Cyto 1.04±0.73 1.86±1.80 2.94±3.56 3.69±3.23 2.72±4.06 1.83±1.04 0.52±0.84 0.39±0.37
Mem 112±85 73±42 19.50±12.53 19.39±9.41 305±87 252±61 11.98±12.58 7.05±4.28
Trans
Cyto 0.23±0.08 0.39±0.46 0.98±1.18 1.52±1.86 0.17±0.28 0.19±0.25 0.16±0.21 0.18±0.25
Mem 11.67±14.75 7.97±3.21 1.44±0.99 7.95±6.39* 4.56±0.96 4.58±2.01 0.72±0.39 0.74±1.16
Total
Cyto 9.58±2.27 11.47±7.32 19.54±19.79 26.84±13.27 8.57±11.29 8.10±4.17 1.43±1.14 1.84±0.93
Mem 736±522 627±387 124±40 182±73* 620±163 562±117 41±26 30±8
Total 745±520 638±388 142±45 209±77* 628±164 569±116 42±26 32±8
Values are means ± SD
* p<0.05 men with NGT vs type 2 diabetes, unpaired samples t test
Cyto, cytosolic fraction; FA, fatty acid; Mem, membrane fraction; MUFA, monounsaturated fatty acid; PL, phospholipids; PUFA, polyunsaturated
fatty acid; SFA, saturated fatty acid; Trans, trans fatty acid
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Discussion
To our knowledge, the present study is the first to examine
insulin resistance of abdominal subcutaneous AT and SM
lipolysis in long-term-diagnosed obese type 2 diabetic men
compared with men with NGT, matched for age, body com-
position and physical fitness. The main finding of the present
study is that long-term diagnosed type 2 diabetic men dem-
onstrated a blunted insulin-induced decrease in muscle lipol-
ysis and higher saturated DAG content in the SM membrane
fraction. Moreover, the membrane content of saturated DAG
was inversely associated with insulin sensitivity and the
insulin-mediated decrease in interstitial SM glycerol concen-
tration. No differences in the insulin sensitivity of AT lipolysis
were found.
Previous studies have yielded conflicting data regarding
sensitivity to the antilipolytic effects of insulin in abdominal
subcutaneous AT and SM. Insulin sensitivity of SM lipolysis
has been suggested to be lower [21] or higher [20] compared
with subcutaneous AT [20]. Moreover, it has been suggested
that SM lipolysis is primarily regulated by substrate supply
and is, to a lesser degree, under hormonal control [29]. This
concept of differential regulation of AT and SM lipolysis is
supported by the presence of different phosphodiesterase and
adrenoceptor subtypes in these tissues [30, 31]. Our data
suggest a clear antilipolytic effect of insulin in both the ab-
dominal subcutaneous AT and SM of obese men with NGT.
The relative decreases in AT (≈ −47%) and SM (≈ −53%)
lipolysis were comparable in men with NGT, indicating tight
insulin-mediated regulation of AT and SM lipolysis in men
with NGT. This may contribute to an adequate switch between
fatty acid and glucose substrate use under postprandial condi-
tions and is of importance for the maintenance of normal
glucose tolerance.
In contrast, type 2 diabetic men showed differential reg-
ulation of AT and SM lipolysis with increased fasting inter-
stitial glycerol concentrations and a blunted decrease (≈ −27%)
in muscle interstitial glycerol during hyperinsulinaemia
(40 mU m−2 min−1). Additionally, muscle lactate concentra-
tions were increased in type 2 diabetic muscle, indicative of an
increased glycolytic flux during hyperinsulinaemic conditions.
This is the first study showing an impaired muscle lipolysis
during hyperinsulinaemia in type 2 diabetic men, whichmay be
associated with the accumulation of lipid metabolites and im-
paired insulin sensitivity, as discussed further below. AT glyc-
erol concentrations were comparable between men with type 2
diabetes and NGT during both baseline and hyperinsulinaemic
conditions. Data on the insulin sensitivity of abdominal subcu-
taneous AT in obese or type 2 diabetic participants are not
consistent [12, 13, 22, 32–35]. This discrepancy remains to
be elucidated but differences between AT depots (e.g. upper vs
lower body and subcutaneous vs visceral) in the ability of
insulin to suppress fatty acid release may possibly contribute
to this [36]. Therefore, there is an urgent need to investigate
other AT depots with respect to insulin resistance of systemic
fatty acid release.
Baseline mRNA expression of ATGL and HSL and HSL
protein content were reduced in type 2 diabetic muscle.
Nevertheless, our data show that despite a fourfold lower
total HSL protein content in muscle of type 2 diabetic men,
total HSL serine 660 phosphorylation and the ratio of phos-
phorylated HSL serine 660 to total HSL was significantly
higher at baseline in type 2 diabetic men compared with
controls. This increased phosphorylation might reflect in-
creased HSL activity, possibly explaining the reduced sup-
pression of lipolysis at baseline in muscle of type 2 diabetic
men (reflected by increased interstitial glycerol concentra-
tions). Nevertheless, lipolytic regulation is complex and the
regulation of lipolysis under hyperinsulinaemic conditions is
governed by different mechanisms than under basal fasting
conditions. Therefore, it remains to be determined whether
increased HSL activity is responsible for the blunted insulin-
mediated suppression of lipolysis in the muscle of type 2
diabetic men.
ATGL protein content was comparable between groups,
while in previous studies increased ATGL protein content
has been reported in type 2 diabetic muscle [18, 19]. In the
present study, in contrast to previous studies, type 2 diabetic
men and NGT controls were matched not only for age and
BMI but also for aerobic capacity (V
⋅
O2max ). Given the fact
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Fig. 5 Relationship between saturated DAG content in the muscle
membrane and: GIR (r=−0.568, p<0.01) (a); the percentage decrease
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that muscle ATGL activity might produce lipid ligands reg-
ulating mitochondrial function via PPARα target genes [37],
matching for aerobic capacity might explain the discrepancy
with previous studies [18, 19]. Furthermore, our study is the
first to show that ATGL serine 404 phosphorylation tends to
be lower in muscle of type 2 diabetic men. The contribution
of ATGL phosphorylation to intracellular lipid accumulation
and the development of insulin resistance and type 2 diabetes
needs to be investigated in future research.
Given the fact that ATGL and HSL are responsible for
more than 95% of the TAG hydrolase activity [38], impaired
intracellular lipolysis may have major effects on the accumu-
lation of cellular lipids, in particular DAG, which could inter-
fere with insulin-mediated signal transduction. There are three
distinct DAG isomers (sn-1,3; sn-2,3; and sn-1,2 DAG). To
date, only sn-1,2 DAG has been associated with insulin sig-
nalling and PKC activation [39, 40]. However, both ATGL
and HSL lack the ability to generate 1,2-DAG in vitro and it
remains to be determined whether lipid droplet-derived DAG
may translocate to the membrane and activate PKC [41].
At present, it is unknown whether stereoselectivity of
ATGL and HSL is impaired under insulin-resistant conditions.
Here, we show for the first time that blunted insulin-mediated
inhibition of SM lipolysis is positively associated with mem-
brane DAG in type 2 diabetic men. The relationship was
particularly strong with the amount of saturated 16:0 and
18:0 DAG in the muscle membrane. These data strengthen
previous observations from our group and others that, in
particular, saturated DAG has a negative impact on insulin
sensitivity [42, 43] and that increased membrane localisation
may mediate this relationship [8]. Furthermore, the proportion
of PKCδ in the muscle membrane was increased in type 2
diabetic men and the saturated DAG content of the membrane
was positively associated with PKC activation, as shown
previously [5]. Several reports in the literature suggest that
saturated DAGs are related to PKC activation [42, 44]. How-
ever, several other PKC isoforms might be involved in the
relationship between membrane DAG and insulin sensitivity.
Together, our data indicate that a lipolytic imbalance may
promote saturated DAG accumulation in the muscle mem-
brane and worsen insulin resistance (i.e. glucose disposal), at
least in part through a PKC-dependent pathway, as has been
suggested recently in vitro in human primary myotubes [19].
Some limitations of our study need to be addressed. Inter-
stitial glycerol was used as a measure of lipolysis. There are
indications from our laboratory that AT and SM may take up
glycerol [17, 45] and may exhibit significant glycerol kinase
activity [46]. This suggests that interstitial glycerol may not
reflect the overall rate of lipolysis, but may instead be the net
result of TAG and glycerol metabolism in the tissue and thus
reflect glycerol turnover [21]. However, this seems unlikely, as
SM GK mRNA expression was comparable between groups
(ESM Fig. 3a). A second consideration is that there is
evidence for an active transport system of insulin across the
blood–tissue barrier, such that insulin concentrations in the
interstitium of AT and SM are approximately 50% of those
in plasma [47, 48]. Although a delayed transcapillary transport
of insulin to muscle interstitial fluid has been observed in
obese compared with lean men [49], this has not been ob-
served inmuscle of type 2 diabetic men compared with healthy
age- and BMI-matched controls [50]. Nevertheless, we cannot
exclude that the impaired insulin-mediated lipolysis in type 2
diabetic muscle is, in part, the result of reduced interstitial
insulin concentrations. Third, the muscle membrane fraction
was not only composed of plasma membranes but contained
other membranes, including mitochondrial and ER, as in-
dicated by the expression of the ER-marker BIP in the
membrane fraction (ESM Fig. 4). As TAG is synthesised
and packed in lipid droplets at the ER, this might explain
the large amount of TAG in the crude membrane fraction.
Taken together, this is the first report of a blunted insulin-
mediated suppression of SM lipolysis in long-term-diagnosed
obese type 2 diabetic men compared with well-matched men
with NGT. The impaired antilipolytic effect of insulin in
skeletal muscle was accompanied by excessive accumulation
of saturated DAG in the SM membrane and reduced glucose
disposal. Together, our data highlight the importance of satu-
rated DAG in themembrane as a potential mechanism involved
in the progression of insulin resistance in type 2 diabetic men.
Therefore, nutritional and pharmacological approaches to de-
crease the degree of saturation of membrane DAG composition
might promote insulin sensitivity in humans.
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